

Research

*Corresponding author

Daisuke Tsuruya, MD

Second Division

Department of Medicine

Hamamatsu University School of

Medicine, 1-20-1 Handayama

Higashi-ku, Hamamatsu

431-3192, Japan

Tel. +81-53-435-2263

Fax: +81-53-435-2354

E-mail: dtsuri0108@future.ocn.ne.jp

Volume 1 : Issue 2

Article Ref. #: 1000DROJ1105

Article History

Received: April 8th, 2015

Accepted: April 16th, 2015

Published: April 17th, 2015

Citation

Tsuruya D, Morita H, Morioka T, Sasaki S, Oki Y, Nakamura H. Additive and antagonistic effects among combination of agonists of peroxisome proliferator-activated receptor gamma (PPAR γ) on transcriptional activity. *Diabetes Res Open J.* 2015; 1(2): 27-33. doi: [10.17140/DROJ-1-105](https://doi.org/10.17140/DROJ-1-105)

Copyright

©2015 Tsuruya D. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Additive and Antagonistic Effects Among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPAR γ) on Transcriptional Activity

Daisuke Tsuruya*, Hiroshi Morita, Tetsu Morioka, Shigekazu Sasaki, Yutaka Oki and Hirotohi Nakamura

Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

ABSTRACT

Objective: The Angiotensin-II receptor blocker telmisartan and sulfonylurea glimepiride may have clinical usefulness as partial agonists of PPAR γ . We investigated additive and antagonistic effects among combinations of telmisartan, glimepiride, and the Thiazolidinedione (TZD) selective PPAR γ agonist pioglitazone on transcriptional activity of PPAR γ .

Materials/Methods: The receptors of pCMX-PPAR γ and pCMX-RXR, and PPRE-Luc reporter gene were transfected into CV1 cells, and treated with following agents, and luciferase assay was performed. Moreover, mammalian two-hybrid assay was done using GAL4 responsive reporter tk-MH100(UAS) \times 4-Luc and the chimeric receptor GAL4-PPAR γ .

Results: Telmisartan increased transactivation of PPAR γ dose dependently. Activation by telmisartan 10 μ M was 58.8% of that by pioglitazone 10 μ M. Glimepiride also increased transactivation of PPAR γ dose dependently. Activation by glimepiride 10 μ M was 49.8% of that by pioglitazone 10 μ M. Addition of telmisartan 5 μ M significantly enhanced transactivation by glimepiride 10 and 50 μ M. Moreover, addition of pioglitazone 0.5 μ M significantly enhanced transactivation by glimepiride 10 and 50 μ M. Mammalian two-hybrid assay showed additive effect between glimepiride and telmisartan on binding of SRC-1 to PPAR γ . On the other hand, addition of glimepiride 10 and 50 μ M reduced transactivation by pioglitazone 5 μ M to 74% and 70%, respectively.

Conclusion: Partial agonists of PPAR γ additively enhanced transactivation by other agonists, whereas high concentration of partial agonists reduced transactivation by full agonist antagonistically.

KEYWORDS: Glimepiride; Telmisartan; Pioglitazone; Nuclear receptor.

ABBREVIATIONS: ARB: Angiotensin-II receptor blocker; PPAR γ : Peroxisome proliferator-activated receptor gamma; PPRE-Luc: PPAR responsive element-luciferase; TZD: Thiazolidinedione.

INTRODUCTION

Peroxisome proliferator-activated receptor gamma (PPAR γ) is a transcriptional factor involved in adipocyte differentiation and insulin sensitization.^{1,2} It forms a heterodimer with retinoid X receptor and binds to peroxisome proliferator responsive elements in the promoter of target genes and regulates their expression.^{3,4} The thiazolidinedione derivative (TZD) pioglitazone is a high-affinity ligand of PPAR γ and clinically useful insulin sensitizer.⁵ However, pioglitazone therapy is associated with adverse effects such as weight gain, edema, and fluid retention; therefore, new agents that activate PPAR γ with less adverse effects are expected.

Recently, it was reported that the Angiotensin-II receptor blocker (ARB) telmisartan⁶⁻¹⁷ and sulfonyleurea glimepiride act as ligands of PPAR γ ^{18,19} and their clinical usefulness in this context has received some attention, although characterization of these new PPAR γ ligands has not been fully clarified. Crystal structure of PPAR γ binding domains revealed a large binding pocket, which may explain the diversity of PPAR γ ligands.^{20,21} Indeed, some studies showed that telmisartan bound to different sites of PPAR γ from TZDs, and recruited coactivators/corepressors in different manner from TZDs.^{6-8,20} Although the characterization of glimepiride has not been clearly determined, glimepiride has been reported to have extra pancreatic effects or actions of improving insulin sensitivity as well as stimulatory effect on islet beta-cells.^{22,23} The extrapancreatic effects of glimepiride would be partly originated from activation of PPAR γ . Therefore, interactions of these ligands should be studied to determine their metabolic efficacy for the development of new therapeutic strategies against insulin resistance and type 2 diabetes. Namely, combination therapy of telmisartan with glimepiride might enhance PPAR γ activity without adverse effects caused by TZDs.

We investigated additive and antagonistic effects among combinations of PPAR γ ligands such as pioglitazone, telmisartan, and glimepiride on transcriptional activity of PPAR γ , and speculated the efficacy of combination therapy by these agents in clinical use.

MATERIALS AND METHODS

Materials

Pioglitazone was a kind gift from Takeda Chemical Industries (Osaka, Japan). Telmisartan and glimepiride were kind gifts from Boehringer-Ingelheim (Tokyo, Japan) and Sanofi-Aventis Pharma (Tokyo, Japan), respectively.

Plasmids

The human RXR expression plasmid pCMX-RXR, human PPAR γ expression plasmid pCMX-PPAR γ , and Luciferase (Luc) reporter gene containing the tk promoter fused to three copies of the PPRE derived from rat AOX, (tk-[PPRE] \times 3-Luc), were described elsewhere.²⁴ GAL4 responsive reporter tk-MH100(UAS) \times 4-Luc and the chimeric receptor GAL4-PPAR γ were also previously described.²⁴ The expression plasmid SRC-1 fused with GAL4 DNA binding domain GAL4-SRC-1 was described elsewhere.^{24,25}

Cell Culture and Transient Transfection

The monkey kidney cell line CV1 was grown in DMEM containing 10% fetal bovine serum, penicillin G (100 U/ml), and streptomycin (100 mg/ml) at 37 °C under 5% CO₂. CV1 cells were trypsinized and seeded at a density of 2 \times 10⁵ cells/well in 6-well plates. Using the calcium phosphate technique, the cells were co-transfected with receptor of GAL4-PPAR γ and

tk-(MH100) \times 4-Luc reporter gene. In the other experiment, the CV1 cells were also co-transfected using the same method with receptors of pCMX-PPAR γ and PPRE-Luc reporter gene. The total amount of transfected plasmid was adjusted to 2 μ g/well by adding empty vector (pCMX). After transfection for 20 h, the medium was replaced with fresh DMEM containing 10% Dextran-coated charcoal-stripped (DCC) fetal bovine serum (10% DCC serum) in the presence or absence of ligands. After 24 h incubation, the cells were harvested and Luc activity was measured. Transfection efficiencies were normalized by galactosidase assay. For interassay control, we performed transfection with Rous Sarcoma Virus (RSV)-Luc (20 ng/well), the magnitude of which was adjusted to 100.

Mammalian Two-Hybrid Assay

Using calcium phosphate technique CV1 cells in 6-well plates were co-transfected with 800 ng Luc reporter gene containing tk-(MH100) \times 4 promoter, 1 μ g of β -galactosidase expression plasmid, 900 ng of expression plasmid for hPPAR γ fused with VP16 transactivating domain, and 360 ng of plasmid for SRC-1 fused with GAL4 DNA binding domain. pCMX was added to adjust the total DNA amount. After incubation for 24 h, the cells were harvested and Luc activities measured and normalized with β -galactosidase activity.

Statistical Analysis

Results are expressed as mean \pm SD from \geq 4 transfections performed in duplicate. Data were analyzed by ANOVA post hoc tests versus control using Stat View 4.0 software (Abacus Concepts, Berkley, CA, USA). P<0.05 was considered significant.

RESULTS

Dose-Dependent Transactivation of PPAR γ by Pioglitazone, Telmisartan, and Glimepiride

Telmisartan and glimepiride as well as pioglitazone increased transactivation of PPAR γ dose dependently using the chimeric receptor GAL4-PPAR γ and the GAL4-responsive reporter of tk-(MH100) \times 4-Luc (Figure 1A). Telmisartan \geq 1 μ M activated PPAR γ significantly, as did glimepiride \geq 5 μ M. Transcriptional activity by 10 μ M of telmisartan and 10 μ M of glimepiride was 58.8% and 49.8% of that by 10 μ M of pioglitazone. Telmisartan and glimepiride increased transactivation of PPAR γ dose dependently on the PPRE using the receptor of PPAR γ and PPAR γ responsive reporter (PPRE) \times 3-Luc (Figure 1B). Transcriptional activity by 10 μ M of telmisartan and 10 μ M of glimepiride was 53.9% and 49.8% of that by 10 μ M of pioglitazone. These results suggest that telmisartan and glimepiride bind to and transactivate PPAR γ and thereby act as partial agonists of PPAR γ .

Additive Effects of Telmisartan on Transactivation of PPARγ by Glimepiride

Telmisartan 5 μM potentiated transactivation of PPARγ additively by each concentration of glimepiride using the chimeric receptor GAL-4 PPARγ and the reporter of tk-(MH100)×4-Luc. Especially, significantly increased activations by 10 and 50 μM of glimepiride were potentiated by addition of 5 μM of telmisartan (Figure 2A). Furthermore, 5 μM of telmisartan potentiated transactivation of PPARγ by each concentration of glimepiride on PPRE using the receptor of PPARγ and reporter of (PPRE)×3-Luc. In particular, significantly increased activations by 10 and 50 μM of glimepiride were potentiated by addition of 5 μM of telmisartan (Figure 2B).

Additive Effects of Pioglitazone on Transactivation of PPARγ by Glimepiride

Pioglitazone 0.5 μM potentiated transactivation of PPARγ additively by each concentration of glimepiride using the chimeric receptor GAL4-PPARγ and the reporter of tk-(MH100)×4-Luc. Especially, significantly increased activations by 10 and 50 μM of glimepiride were potentiated by addition of

0.5 μM of pioglitazone (Figure 3A). Furthermore, 0.5 μM of pioglitazone potentiated transactivation of PPARγ by each concentration of glimepiride on PPRE using the receptor of PPARγ and reporter of (PPRE)×3-Luc. In particular, significantly increased activations by 10 and 50 μM of glimepiride were potentiated by addition of 0.5 μM of pioglitazone (Figure 3B).

Antagonistic Effects Glimepiride on Transactivation of PPARγ by Pioglitazone

High concentrations (10 and 50 μM) of glimepiride reduced transactivation of PPARγ by 5 μM of pioglitazone using the chimeric receptor GAL4-PPARγ and the reporter of tk-(MH100)×4-Luc (Figure 4A). Moreover, 50 μM of glimepiride reduced transactivation of PPARγ by 5 μM of pioglitazone using the receptor of PPARγ and reporter of (PPRE)×3-Luc (Figure 4B).

Additive Binding Activity of PPARγ to SRC-1 by Glimepiride and Telmisartan

To examine the additive effects of glimepiride and telmisartan on the interaction of PPARγ with co-activator, mam-




Figure 1: Dose-dependent transactivation of PPARγ by pioglitazone, telmisartan, and glimepiride. (A) Chimeric receptor of GAL4-PPARγ and GAL4 responsive reporter of tk-MH100(UAS)×4-Luc were transfected into CV1 cells in the absence or presence of various ligands. Increasing amounts of ligand were added. Luciferase activities induced by pioglitazone (Piog; closed bar), telmisartan (Telm; grey bar), and glimepiride (Glim, open bar) are represented. (B) Receptors of PPARγ and R×R expression plasmids were transfected into CV1 cells together with PPRE-tk-Luc in the absence or presence of various ligands. Increasing amounts of ligand were added. Luciferase activities induced by Piog (closed bar), Telm (grey bar), and Glim (open bar) are represented. Results are mean ± SD from indicated numbers of transfections in duplicate. *P<0.05; §P<0.05 vs. control (no ligand).




Figure 2: Additive effects of telmisartan on transactivation of PPARγ by glimepiride. (A) Chimeric receptor of GAL4-PPARγ and GAL4 responsive reporter of tk-MH100(UAS)×4-Luc were transfected into CV1 cells in the absence or presence of increasing concentrations of glimepiride together with (closed bar) or without 5 μM of telmisartan (open bar). (B) Receptor of PPARγ and R×R expression plasmids were transfected into CV1 cells together with PPRE-tk-Luc in the absence or presence of increasing concentrations of glimepiride together with (closed bar) or without 5 μM of telmisartan (open bar). Results are mean ± SD from indicated numbers of transfections in duplicate. §P<0.05 vs. respective control: (no ligand).




Figure 3: Additive effects of low concentration of pioglitazone on transactivation of PPAR γ by glimepiride. (A) Chimeric receptor of GAL4-PPAR γ and GAL4 responsive reporter of tk-MH100 (UAS) \times 4-Luc were transfected into CV1 cells in the absence or presence of increasing concentrations of glimepiride together with (closed bar) or without 0.5 μ M of pioglitazone (open bar). (B) Receptor of PPAR γ and R \times R expression plasmids were transfected into CV1 cells together with PPRE-tk-Luc in the absence or presence of increasing concentration of glimepiride together with (closed bar) or without 0.5 μ M of pioglitazone (open bar). Results are mean \pm SD from indicated numbers of transfections in duplicate. *P<0.05; §P<0.05 vs. control (no ligand).




Figure 4: Antagonistic effects of glimepiride on transactivation of PPAR γ by pioglitazone. (A) Chimeric receptor of GAL4-PPAR γ and GAL4 responsive reporter of tk-MH100(UAS) \times 4-Luc were transfected into CV1 cells in the absence or presence of increasing concentration of glimepiride together with (closed bar) or without 5 μ M of pioglitazone (open bar). (B) Receptor of PPAR γ and R \times R expression plasmids were transfected into CV1 cells together with PPRE-tk-LUC in the absence or presence of increasing concentration of glimepiride together with (closed bar) or without 5 μ M of pioglitazone (open bar). Results are mean \pm SD from indicated numbers of transfections in duplicate. *P<0.05; §P<0.05 vs. control (no ligand).

malian two-hybrid assay using VP16-PPAR γ , GAL4-SRC-1, and the reporter of GAL-Luc was performed. Both glimepiride and telmisartan enhanced Luc activity by the binding between VP16-PPAR γ and GAL4-SRC-1. The interaction between VP16-PPAR γ and GAL4-SRC-1 was more enhanced by addition of both glimepiride and telmisartan than by that of glimepiride or telmisartan alone (Figure 5).

DISCUSSION

Telmisartan directly activated PPAR γ dose dependently; telmisartan 10 μ M activated transcriptional system using GAL4-PPAR γ chimera receptor and GAL4 responsive reporter gene and that using receptor of PPAR γ and reporter gene including PPRE to 58.8% and 53.8% of the level achieved by 10 μ M of pioglitazone, respectively. These data suggest that telmisartan binds and activates PPAR γ because the structure of telmisartan is similar to that of TZD. Glimepiride 10 μ M also activated PPAR γ to 49.8% of the level by 10 μ M of pioglitazone in similar condi-




Figure 5: Additive effects of glimepiride and telmisartan on binding between PPAR γ and SRC-1. Receptor of GAL4-PPAR γ and SRC-1 expression plasmids were transfected into CV1 cells together with tk-MH100(UAS) \times 4-Luc in the absence or presence of glimepiride and/or 5 μ M of telmisartan. Results are mean \pm SD from indicated numbers of transfections in duplicate. *P<0.05; §P<0.05 vs. control (no ligand).

tions. Although the structure of glimepiride is different from that of TZD, these data suggest that nonetheless glimepiride binds and activates PPAR γ . The binding pocket of PPAR γ is large and glimepiride might bind to PPAR γ in different manner from TZD.

These two ligands act as partial agonists of PPAR γ as previously reported, although other ARBs (except irbesartan), and other sulfonilureas do not increase transactivation of PPAR γ .^{6-8,22} CV1 cells were used in the present experiment to estimate the interactions of these ligands. It would be necessary to confirm these interactions in adipocytes expressed of PPAR γ . Telmisartan binds to helices H3 and H7 of LBD of PPAR γ does TZD and other partial agonists of PPAR γ .^{7,26,27} Difference of binding ability (to H12) might bring different degrees of activation of PPAR γ . The carboxy terminal activation domain (AF-2) in H12 of LBD is proposed to undergo induced conformational changes after binding to ligand.^{20,21,28,29} The present experiment showed that two ligands, glimepiride and telmisartan, had additive activations of PPAR γ , suggesting that each ligand did not change binding capacity to the receptor of PPAR γ for each ligand. Recent study showed that some combinations of ligands, fatty acid and indole acetate or indomethacin, induce additive or synergistic activation of PPAR γ .²⁷ This study confirmed the data about the combination effect of telmisartan and glimepiride. We do not have definitive data about the binding site of glimepiride to PPAR γ . However, it was reported that glimepiride competitively binds PPAR γ with rosiglitazone, suggesting that glimepiride has partly similar binding site of PPAR γ to TZD.¹⁸

Because different ligands of PPAR γ might recruit co-activator in different manner, interactions about the recruitment of coactivator by each ligand should be investigated. The present results suggest that telmisartan, glimepiride, and pioglitazone induced interactions between PPAR γ and SRC-1 depending on the transcriptional activity of PPAR γ (data not shown). Glimepiride also induced additive interaction between PPAR γ and SRC-1. As for SRC-1, these ligands recruited the coactivator to PPAR γ depending on the activity, although different ligands were reported to recruit coactivators such as DRIP205, TIF-2, and PGC-1 in different manners.^{6,8,20} A previous article reported that DRIP205 was recruited by rosiglitazone and telmisartan in similar degree, and PGC-1 by rosiglitazone and telmisartan depending on the transcriptional activity of PPAR γ , whereas TIF-2 was recruited not by telmisartan but by rosiglitazone. These findings suggest that SRC-1 and PGC-1 were recruited by ligands depending on the transcriptional activity of PPAR γ , but not TIF-2. Different manners of cofactor recruitment would result in different induction of genes. Schuup, et al.⁶ suggested the genes of prostacyclin receptor and glycerol kinase induced by TZDs were less stimulated by ARBs, and that these ligands had some transcriptional activity of PPAR γ with less side effects including edema or body weight gain.

A number of clinical trials reported that telmisartan im-

proved insulin sensitivity and lowered plasma triacylglycerides in type 2 diabetic patients.³⁰⁻³² These effects were remarkably prominent by administration of telmisartan among all ARBs, suggesting that the observed effects might originate from activation of PPAR γ . Glimepiride has been reported to stimulate insulin secretion with less increasing of body weight. These effects might originate from stimulating activity of PPAR γ with less effect inducing edema or retention of body fluid. Clinically, combination therapy of telmisartan with glimepiride is suggested to induce additive effect on activity of PPAR γ . Although clinically approved doses of telmisartan and glimepiride individually have only slight effect on activation of PPAR γ , the combination therapy of both drugs might bring additive effects on activation of PPAR γ . Although we have no definite data about combination therapy of glimepiride and telmisartan improving insulin sensitivity, these drugs would potentially induce additively transcriptional activity of PPAR γ without side effects. This combination therapy might provide a new therapeutic option for better cardiovascular management in metabolic diseases and might initiate the development of new classes of combination therapy. Furthermore, activity of PPAR γ by natural ligand might be potentiated by these agents.

On the other hand, our data showed that high concentrations of glimepiride and telmisartan inhibited activity of PPAR γ by pioglitazone. Previous *in vitro* experiments showed that partial agonists inhibited adipocyte differentiation stimulated by TZDs.³³ However, it seems improbable that glimepiride and telmisartan would clinically inhibit activity of pioglitazone on PPRE, because clinical doses of glimepiride and telmisartan bring only low concentration (1 μ M) in blood stream. Contrarily, there are some reports that telmisartan had some beneficial metabolic effects in type 2 diabetic patients and animal models treated with rosiglitazone. Derosa, et al.³⁴ reported that administration of telmisartan improved glucose tolerance in type 2 diabetic patients treated with rosiglitazone without body weight gain. Zanchi, et al.³⁵ reported that telmisartan prevented pioglitazone-induced weight gain in Zucker fatty rats without interfering with its insulin-sensitizing properties. It has been suggested that telmisartan prevents weight gain and obesity through activation of PPAR delta-dependent pathways.³⁶ Clinically, combined administration of telmisartan and low-dose pioglitazone would be an attractive therapy with respect to weight control because it might improve insulin sensitivity with less increase of edema than pioglitazone monotherapy.

In conclusion, we observed additive effects of PPAR γ partial agonists such as telmisartan and pioglitazone on transcriptional activities of PPAR γ , suggesting that combination therapies with these agents might improve insulin sensitivity in type 2 diabetic patients with few side effects.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

ACKNOWLEDGMENTS

We thank Dr. Makishima and colleagues at Nihon University for plasmids used in this study.

REFERENCES

1. Tontronoz P, Hu E, Craves RA, et al. MPPAR-gamma2:tissue specific regulator of an adipocyte enhancer. *Genes Dev.* 1994; 8: 1224-1234. doi: [10.1101/gad.8.10.1224](https://doi.org/10.1101/gad.8.10.1224)
2. Chawia A, Schwarz EJ, Dimaculangan DD, et al. Peroxisome proliferator-activated receptor gamma (PPAR): Adipose predominant expression and induction early in adipocyte differentiation. *Endocrinology.* 1994; 135: 798-800. doi: [10.1210/endo.135.2.8033830](https://doi.org/10.1210/endo.135.2.8033830)
3. Wu Z, Rosen ED, Brun R, et al. Cross-regulation of C/EBPalpha and PPARgamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. *Molecular cell.* 1999; 3: 151-158. doi: [10.1016/S1097-2765\(00\)80306-8](https://doi.org/10.1016/S1097-2765(00)80306-8)
4. Gampe RT, Montana VG, Lambert MH, et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. *Molecular cell.* 2000; 5: 545-555. doi: [10.1016/S1097-2765\(00\)80448-7](https://doi.org/10.1016/S1097-2765(00)80448-7)
5. Lehmann JM, Moor LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor gamma (PPAR-gamma). *J. Biol. Chem.* 1995; 270: 12953-12956. doi: [10.1074/jbc.270.22.12953](https://doi.org/10.1074/jbc.270.22.12953)
6. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor modulators with angiotensin receptor blocking activity. *Diabetes.* 2005; 54: 3442-3452. doi: [10.2337/diabetes.54.12.3442](https://doi.org/10.2337/diabetes.54.12.3442)
7. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR modulation activity. *Hypertension.* 2004; 43: 993-1002. doi: [10.1161/01.HYP.0000123072.34629.57](https://doi.org/10.1161/01.HYP.0000123072.34629.57)
8. Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPAR by angiotensin II type 1-receptor antagonists. *Vascular Pharmacology.* 2006; 45(3): 154-162. doi: [10.1016/j.vph.2006.05.002](https://doi.org/10.1016/j.vph.2006.05.002)
9. Imayama I, Ichiki T, Inanaga K, et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. *Cardiovascular research.* 2006; 72: 184-190. doi: [10.1016/j.cardiores.2006.07.014](https://doi.org/10.1016/j.cardiores.2006.07.014)
10. Fujimoto M, Masuzaki H, Tanaka T, et al. An angiotensin II AT1 receptor antagonists, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. *FEBS letters.* 2004; 576: 492-497. doi: [10.1016/j.febslet.2004.09.027](https://doi.org/10.1016/j.febslet.2004.09.027)
11. Nakaya K, Ayaori M, Hisada T, et al. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. *J Atherosclerosis Thromb.* 2007; 14: 133-141. doi: [10.5551/jat.14.133](https://doi.org/10.5551/jat.14.133)
12. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor. *The International Journal of Biochemistry & Cell Biology.* 2005; 766-781. doi: [10.1016/j.biocel.2005.08.006](https://doi.org/10.1016/j.biocel.2005.08.006)
13. Haraguchi T, Takasaki K, Naito T, et al. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via peroxisome proliferator-activated receptor gamma-dependent mechanism. *Neuroscience letters.* 2009; 464: 151-155. doi: [10.1016/j.neulet.2009.08.043](https://doi.org/10.1016/j.neulet.2009.08.043)
14. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 blockers induce peroxisome proliferator-activated receptor gamma activity. *Circulation.* 2004; 109: 2054-2057. doi: [10.1161/01.CIR.0000127955.36250.65](https://doi.org/10.1161/01.CIR.0000127955.36250.65)
15. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through down regulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. *J Int Med Res.* 2007; 35: 482-489.
16. Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. *Diabetologia.* 2006; 49: 3094-3099. doi: [10.1007/s00125-006-0437-7](https://doi.org/10.1007/s00125-006-0437-7)
17. Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. *J Hypertens.* 2006; 24: 1809-1816. doi: [10.1097/01.hjh.0000242405.68461.84](https://doi.org/10.1097/01.hjh.0000242405.68461.84)
18. Fukuen S, Iwaki M, Yasui A, et al. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor antagonistic activity. *J Biol Chem.* 2005; 280: 23653-23659. doi: [10.1074/jbc.M412113200](https://doi.org/10.1074/jbc.M412113200)
19. Inukai K, Watanabe M, Nakashima Y, et al. Glimpiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. *Biochem Biophys Res Commun.* 2005; 328: 484-490. doi: [10.1016/j.bbrc.2004.12.190](https://doi.org/10.1016/j.bbrc.2004.12.190)
20. Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated

- receptor-g. *Nature*. 1998; 395: 137-143. doi: [10.1038/25931](https://doi.org/10.1038/25931)
21. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPAR gamma. *J Biol Chem*. 1998; 273: 31108-31122. doi: [10.1074/jbc.273.47.31108](https://doi.org/10.1074/jbc.273.47.31108)
22. Muller G, Geise K. Characterization of the molecular mode of action of the sulfonyluream glimepiride, at adipocytes. *Horm-Metab Res*. 1996; 28: 469-487. doi: [10.1055/s-2007-979839](https://doi.org/10.1055/s-2007-979839)
23. Hamaguchi T, Hirose T, Asakawa H, et al. Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide. *Diabetic Res Clin Prac*. 2004; 66: 129-132. doi: [10.1016/j.diabres.2003.12.012](https://doi.org/10.1016/j.diabres.2003.12.012)
24. Suzuki S, Sasaki S, Morita H, et al. The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gamma2 with nuclear receptor co-repressor. *J Mol Endocrinol*. 2010; 45: 1-14.
25. Kawai K, Sasaki S, Morita H, Ito T, et al. Unliganded thyroid hormone receptor-beta1 represses liver X receptor alpha/oxysterol-dependent transactivation. *Endocrinology*. 2004; 145: 5515-5524. doi: [10.1210/en.2004-0382](https://doi.org/10.1210/en.2004-0382)
26. Tagami T, Yamamoto H, Moriyama K, et al. A selective proliferator-activated receptor- modulator, telmisartan, binds to the receptor in a different fashion from thazolidonedions. *Endocrinology*. 2009; 150: 862-870. doi: [10.1210/en.2008-0502](https://doi.org/10.1210/en.2008-0502)
27. Waku T, Shiraki T, Oyama T, et al. The nuclear receptor of PPAR gamma individually responds to serotonin- and fatty acid-metabolites. *EMBO Journal*. 2010; 29: 3395-3407. doi: [10.1038/emboj.2010.197](https://doi.org/10.1038/emboj.2010.197)
28. Berger JP, Petro AN, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein selective modulator. *Mol Endocrinology*. 2003; 17: 662-676. doi: [10.1210/me.2002-0217](https://doi.org/10.1210/me.2002-0217)
29. Xu HE, Lambert MH, Montana VG, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. *Proc Natl Acad Sci*. 2001; 98: 13919-13924. doi: [10.1073/pnas.241410198](https://doi.org/10.1073/pnas.241410198)
30. Chujo D, Yagi K, Asano A, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. *Hypertens Res*. 2007; 30: 1205-1210. doi: [10.1291/hypres.30.1205](https://doi.org/10.1291/hypres.30.1205)
31. Pershadsingh HA, Kurz TW. Insulin-sensitizing effects of telmisartan. *Diabetes care*. 2004; 27: 1015. doi: [10.2337/diacare.27.4.1015](https://doi.org/10.2337/diacare.27.4.1015)
32. Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. *Metabolism*. 2006; 55: 1159-1164. doi: [10.1016/j.metabol.2006.04.013](https://doi.org/10.1016/j.metabol.2006.04.013)
33. Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein selective modulator. *Mol Endocrinol*. 2000; 17: 662-676.
34. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. *Journal of Clinical pharmacy and Therapeutics*. 2007; 32: 261-268. doi: [10.1111/j.1365-2710.2007.00820.x](https://doi.org/10.1111/j.1365-2710.2007.00820.x)
35. Zanchi A, Dulloo AG, Perregaux C, et al. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. *Am J Physiol Endocrinol Metab*. 2007; 293: E91-E95. doi: [10.1152/ajpendo.00024.2007](https://doi.org/10.1152/ajpendo.00024.2007)
36. He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. *Hypertension*. 2010; 55: 869-879. doi: [10.1161/HYPERTENSIONAHA.109.143958](https://doi.org/10.1161/HYPERTENSIONAHA.109.143958)